Page 4 - Nasdaq Mdgl News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) and DMK Pharmaceuticals (NASDAQ:DMK – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation. Risk and Volatility Madrigal Pharmaceuticals has a beta […]

Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) had its price objective hoisted by equities researchers at Piper Sandler from $305.00 to $336.00 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage currently has an “overweight” rating on the biopharmaceutical company’s stock. Piper Sandler’s price target suggests a potential upside of 45.91% […]

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) VP Robert E. Waltermire sold 2,500 shares of the business’s stock in a transaction on Wednesday, December 13th. The stock was sold at an average price of $225.40, for a total value of $563,500.00. Following the sale, the vice president now owns 5,667 shares of the company’s […]

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) Director Bros. Advisors Lp Baker acquired 81,159 shares of Madrigal Pharmaceuticals stock in a transaction dated Wednesday, December 13th. The shares were purchased at an average price of $219.39 per share, for a total transaction of $17,805,473.01. Following the completion of the transaction, the director now directly […]

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) Director Bros. Advisors Lp Baker purchased 64,350 shares of the stock in a transaction dated Tuesday, November 21st. The stock was purchased at an average cost of $188.47 per share, for a total transaction of $12,128,044.50. Following the completion of the acquisition, the director now owns 1,667,104 […]